Segment Data

9 Months Ended

Sep. 30, 2025

Segment Data

Segment Data

14. Segment Data

The Company has two reportable segments: animal health and human health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing human products and the ongoing commercialization of Mytesi, which the US FDA approves for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Company has not disclosed revenue by geographic location as its revenues are distributed across multiple regions without significant concentration in any single area.

The accounting policies used in the segment reporting are the same as those described in the summary significant accounting policies (Note 2). The Company’s CODM is the chief financial officer. The CODM primarily utilizes segment's net comprehensive profit or loss as the key indicator in assessing the segment's performance and allocating resources.

The Company's reportable segments net revenues and net loss for the three and nine months ended September 30, 2025 and 2024, consisted of the following:

	Nine Months Ended									Nine Months Ended
	September 30, 2025									September 30, 2024
(in thousands)	(unaudited)									(unaudited)
	Human Health			Animal Health			Total			Human Health			Animal Health			Total
External revenue	$	8,006		$	270		$	8,276		$	7,954		$	226		$	8,180
Less: Segment expenses
Cost of revenue		1,546			28			1,574			1,356			42			1,398
Research and development		8,750			1,907			10,657			10,000			2,011			12,011
Sales and marketing		6,632			325			6,957			4,768			209			4,977
General and administrative		5,901			9,339			15,240			6,700			7,222			13,922
Interest		5			(70	)		(65	)		87			338			425
Other segment items*		858			5,782			6,640			354			5,697			6,051
Segment expenses		23,692			17,311			41,003			23,265			15,519			38,784
Segment net comprehensive loss	$	(15,686	)	$	(17,041	)	$	(32,727	)	$	(15,311	)	$	(15,293	)	$	(30,604	)
Reconciliation of net comprehensive loss
Adjustments and reconciling items**								1,505									1,547
Consolidated net comprehensive loss							$	(31,222	)							$	(29,057	)

	Three Months Ended									Three Months Ended
	September 30, 2025									September 30, 2024
(in thousands)	(unaudited)									(unaudited)
	Human Health			Animal Health			Total			Human Health			Animal Health			Total
External revenue	$	3,005		$	78		$	3,083		$	3,014		$	94		$	3,108
Less: Segment expenses
Cost of revenue		523			9			532			527			14			541
Research and development		3,036			626			3,662			3,599			446			4,045
Sales and marketing		1,935			62			1,997			1,946			64			2,010
General and administrative		1,898			2,760			4,658			2,288			1,983			4,271
Interest		4			2			6			32			(163	)		(131	)
Other segment items*		393			2,006			2,399			117			3,141			3,258
Segment expenses		7,789			5,465			13,254			8,509			5,485			13,994
Segment net comprehensive loss	$	(4,784	)	$	(5,387	)	$	(10,171	)	$	(5,495	)	$	(5,391	)	$	(10,886	)
Reconciliation of net comprehensive loss
Adjustments and reconciling items**								389									701
Consolidated net comprehensive loss							$	(9,782	)							$	(10,185	)

*Other segment items for each reportable segment include:

•Human Health - realized gain/loss on foreign exchange transactions, changes in fair value of warrants, gain/loss on debt extinguishment and share in net income or loss in joint venture.

•Animal Health - realized and unrealized gain/loss on foreign exchange transactions.

**Adjustments and reconciling items include intercompany elimination entries

The Company's reportable segments assets consisted of the following:

	September 30,		December 31,
	2025		2024
Segment assets
Human Health	$	45,436	$	44,117
Animal Health		181,484		174,803
Total	$	226,920	$	218,920

The Company’s operations were divided into two geographical locations, Europe and the US. The carrying value of fixed assets in Europe totaled $136,000 and $230,000 as of September 30, 2025, and December 31, 2024, respectively. This pertains to a right-of-use asset for the Napo Therapeutics office and vehicle lease. In the US, the carrying value of fixed assets totaled $18.7 million and $19.6 million, respectively, composed of property, plant, and equipment, right-of-use assets, and intangible assets.

The reconciliation of segments assets to the consolidated assets is as follows:

	September 30,			December 31,
	2025			2024
(in thousands)	(unaudited)
Total assets for reportable segments	$	226,920		$	218,920
Less: Investment in subsidiary		(29,231	)		(29,232	)
Less: Intercompany loan		(148,217	)		(136,263	)
Consolidated Totals	$	49,472		$	53,425